NASDAQ:KNSA

Kiniksa Pharmaceuticals . Class A Stock Insider Trading

Healthcare > Biotechnology

Buy KNSA

*Your capital is at risk

$47.85

+0.93 (+1.98%)

At Close: Jun 03, 2026

Kiniksa Pharmaceuticals . Class A Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -77.00. In total, the insiders bought 2.75M and sold 1.56M KNSA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-77.00
● Buy	2.75M shares
● Sell	1.56M shares
76% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 28, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -77. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 29, 2026 Buy	Class A Ordinary Share M-Exempt	Quart Barry D Director	Director	2 799 Value: $135.4K
May 29, 2026 Buy	Share Option A-Award	Quart Barry D Director	Director	12 158 Value: $588.2K
May 29, 2026 Buy	Share Option A-Award	Popovits Kimberly J Director	Director	12 158 Value: $588.2K
May 29, 2026 Buy	Restricted Share Units M-Exempt	Mccain Tracey L Director	Director	2 799 Value: $135.4K
May 01, 2026 Sell	Class A Ordinary Share S-Sale	Paolini John F. Chief Medical Officer	Officer	21 097 Value: $1.14M
May 01, 2026 Buy	Share Option M-Exempt	Paolini John F. Chief Medical Officer	Officer	58 424 Value: $605.3K
May 01, 2026 Sell	Class A Ordinary Share S-Sale	Paolini John F. Chief Medical Officer	Officer	37 327 Value: $2.00M
May 01, 2026 Buy	Class A Ordinary Share M-Exempt	Paolini John F. Chief Medical Officer	Officer	58 424 Value: $605.3K
May 01, 2026 Buy	Class A Ordinary Share M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	48 565 Value: $1.50M
May 01, 2026 Sell	Class A Ordinary Share S-Sale	Patel Sanj K Chairman & CEO	CEO / President	48 565 Value: $2.62M
May 01, 2026 Buy	Share Option M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	48 565 Value: $1.50M
Apr 30, 2026 Buy	Class A Ordinary Share M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	2 141 Value: $66.2K
Apr 30, 2026 Buy	Share Option M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	2 141 Value: $66.2K
Apr 30, 2026 Sell	Class A Ordinary Share S-Sale	Patel Sanj K Chairman & CEO	CEO / President	2 141 Value: $115.6K
Apr 29, 2026 Buy	Class A Ordinary Share M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	22 544 Value: $697.3K
Apr 29, 2026 Buy	Share Option M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	22 544 Value: $697.3K
Apr 28, 2026 Sell	Class A Ordinary Share S-Sale	Patel Sanj K Chairman & CEO	CEO / President	51 750 Value: $2.80M
Apr 28, 2026 Sell	Class A Ordinary Share S-Sale	Patel Sanj K Chairman & CEO	CEO / President	243 596 Value: $12.7M
Apr 28, 2026 Buy	Class A Ordinary Share M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	51 750 Value: $1.60M
Apr 28, 2026 Buy	Class A Ordinary Share M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	431 904 Value: $4.47M
Apr 28, 2026 Sell	Class A Ordinary Share S-Sale	Patel Sanj K Chairman & CEO	CEO / President	74 635 Value: $3.76M
Apr 28, 2026 Sell	Class A Ordinary Share S-Sale	Patel Sanj K Chairman & CEO	CEO / President	113 673 Value: $5.85M
Apr 28, 2026 Buy	Share Option M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	51 750 Value: $1.60M
Apr 28, 2026 Buy	Share Option M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	431 904 Value: $4.47M
Apr 28, 2026 Sell	Class A Ordinary Share S-Sale	Quart Barry D Director	Director	13 099 Value: $656.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KINIKSA PHARMACEUTICALS LTD. CLASS A

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...

Read Full Profile Here